RU2010123381A - Способ и композиции для диагностического применения у раковых пациентов - Google Patents
Способ и композиции для диагностического применения у раковых пациентов Download PDFInfo
- Publication number
- RU2010123381A RU2010123381A RU2010123381/15A RU2010123381A RU2010123381A RU 2010123381 A RU2010123381 A RU 2010123381A RU 2010123381/15 A RU2010123381/15 A RU 2010123381/15A RU 2010123381 A RU2010123381 A RU 2010123381A RU 2010123381 A RU2010123381 A RU 2010123381A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- genes
- therapy
- addition
- gene products
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 22
- 206010028980 Neoplasm Diseases 0.000 title claims 9
- 201000011510 cancer Diseases 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract 46
- 238000011122 anti-angiogenic therapy Methods 0.000 claims abstract 26
- 239000000523 sample Substances 0.000 claims abstract 25
- 238000011319 anticancer therapy Methods 0.000 claims abstract 11
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract 10
- 206010038389 Renal cancer Diseases 0.000 claims abstract 10
- 201000010982 kidney cancer Diseases 0.000 claims abstract 10
- 239000013074 reference sample Substances 0.000 claims abstract 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract 6
- 239000005557 antagonist Substances 0.000 claims abstract 6
- 229960000397 bevacizumab Drugs 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims 16
- 230000007012 clinical effect Effects 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98688407P | 2007-11-09 | 2007-11-09 | |
| US60/986,884 | 2007-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010123381A true RU2010123381A (ru) | 2011-12-20 |
Family
ID=40342593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010123381/15A RU2010123381A (ru) | 2007-11-09 | 2008-11-05 | Способ и композиции для диагностического применения у раковых пациентов |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090123930A1 (enExample) |
| EP (1) | EP2222874A2 (enExample) |
| JP (1) | JP2011502513A (enExample) |
| KR (1) | KR20100095571A (enExample) |
| CN (1) | CN101910416A (enExample) |
| AU (1) | AU2008324782A1 (enExample) |
| BR (1) | BRPI0817158A2 (enExample) |
| CA (1) | CA2703258A1 (enExample) |
| IL (1) | IL205246A0 (enExample) |
| MX (1) | MX2010005057A (enExample) |
| RU (1) | RU2010123381A (enExample) |
| WO (1) | WO2009061800A2 (enExample) |
| ZA (1) | ZA201002808B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177640A1 (en) * | 2009-07-13 | 2012-02-28 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
| KR101557545B1 (ko) * | 2009-09-17 | 2015-10-06 | 에프. 호프만-라 로슈 아게 | 암 환자에서 진단 용도를 위한 방법 및 조성물 |
| CN104634971A (zh) * | 2010-07-19 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌疗法的可能性升高的患者的方法 |
| WO2012010549A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| US10260097B2 (en) | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| CA2862835A1 (en) * | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| WO2014001232A1 (en) * | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| HK1214633A1 (zh) * | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
| US11015190B2 (en) | 2013-09-17 | 2021-05-25 | Lucence Life Sciences Pte Ltd | Method of treating a patient having renal cancer |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| MX2017007535A (es) * | 2014-12-09 | 2017-08-10 | Merck Sharp & Dohme | Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1). |
| KR101903522B1 (ko) * | 2015-11-25 | 2018-11-23 | 한국전자통신연구원 | 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치 |
| WO2025098316A1 (en) * | 2023-11-09 | 2025-05-15 | Sun Jet Biotechnology Inc. | Apolipoprotein a-ii biomarkers for detecting and monitoring cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030027216A1 (en) * | 2001-07-02 | 2003-02-06 | Kiernan Urban A. | Analysis of proteins from biological fluids using mass spectrometric immunoassay |
| EP1869216B1 (en) * | 2005-04-13 | 2012-08-15 | Oncotest GmbH | Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds |
| WO2007123722A2 (en) * | 2006-03-31 | 2007-11-01 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
-
2008
- 2008-11-05 WO PCT/US2008/082456 patent/WO2009061800A2/en not_active Ceased
- 2008-11-05 KR KR1020107012551A patent/KR20100095571A/ko not_active Withdrawn
- 2008-11-05 BR BRPI0817158 patent/BRPI0817158A2/pt not_active IP Right Cessation
- 2008-11-05 AU AU2008324782A patent/AU2008324782A1/en not_active Abandoned
- 2008-11-05 JP JP2010533204A patent/JP2011502513A/ja not_active Withdrawn
- 2008-11-05 EP EP08846956A patent/EP2222874A2/en not_active Withdrawn
- 2008-11-05 RU RU2010123381/15A patent/RU2010123381A/ru not_active Application Discontinuation
- 2008-11-05 US US12/265,143 patent/US20090123930A1/en not_active Abandoned
- 2008-11-05 CN CN2008801243215A patent/CN101910416A/zh active Pending
- 2008-11-05 MX MX2010005057A patent/MX2010005057A/es not_active Application Discontinuation
- 2008-11-05 CA CA2703258A patent/CA2703258A1/en not_active Abandoned
-
2010
- 2010-04-21 ZA ZA2010/02808A patent/ZA201002808B/en unknown
- 2010-04-22 IL IL205246A patent/IL205246A0/en unknown
- 2010-11-19 US US12/950,824 patent/US20110151468A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011502513A (ja) | 2011-01-27 |
| IL205246A0 (en) | 2010-12-30 |
| WO2009061800A3 (en) | 2009-07-16 |
| ZA201002808B (en) | 2011-07-27 |
| US20090123930A1 (en) | 2009-05-14 |
| BRPI0817158A2 (pt) | 2015-04-14 |
| US20110151468A1 (en) | 2011-06-23 |
| CA2703258A1 (en) | 2009-05-14 |
| AU2008324782A1 (en) | 2009-05-14 |
| CN101910416A (zh) | 2010-12-08 |
| WO2009061800A2 (en) | 2009-05-14 |
| EP2222874A2 (en) | 2010-09-01 |
| KR20100095571A (ko) | 2010-08-31 |
| MX2010005057A (es) | 2010-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bruix et al. | Insights into the success and failure of systemic therapy for hepatocellular carcinoma | |
| Heppt et al. | Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma | |
| Tan et al. | Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers | |
| Wills et al. | Role of liquid biopsies in colorectal cancer | |
| WO2009121031A4 (en) | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases | |
| Jones et al. | Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making | |
| CN106148529B (zh) | 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用 | |
| Stangl-Kremser et al. | Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients | |
| JP2011502513A5 (enExample) | ||
| Akabane et al. | Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy | |
| Puente et al. | Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma | |
| Krajewski et al. | Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine | |
| Yan et al. | Molecular biomarker‐guided anti‐angiogenic targeted therapy for malignant glioma | |
| Kim et al. | Effect of fibroblast growth factor-2 and its receptor gene polymorphisms on the survival of patients with hepatitis B virus-associated hepatocellular carcinoma | |
| Jeon et al. | Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans | |
| Nouhaud et al. | Clinical relevance of gene copy number variation in metastatic clear cell renal cell carcinoma | |
| ES2946681T3 (es) | Genes y firmas génicas para el diagnóstico y tratamiento del melanoma | |
| Brissot et al. | Which acute myeloid leukemia patients should be offered transplantation? | |
| Wiemer | Prognostic Circulating MicroRNA Biomarkers in Early‐Stage Non‐Small Cell Lung Cancer: A Role for miR‐150 | |
| Wu et al. | Down-regulation of EGFL8: a novel biomarker for advanced gastric cancer | |
| RU2013155198A (ru) | Экспрессия kiaa1456 предсказывает выживаемость у пациентов с колоректальным раком | |
| Burtyn et al. | 30P Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma | |
| Wang | High expression of sushi domain containing 2 (SUSD2) promote cell proliferation in bladder cancer and was associated poor survival outcome | |
| Das et al. | Spleen cancer: Biomarkers landscape | |
| Jiang et al. | A Study on the Causal Relationships Between Blood Protein Ratios and Hepatobiliary Cancers Based on Mendelian Randomization Models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130729 |